Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Regeneron Pharmaceuticals
(NQ:
REGN
)
802.92
+18.56 (+2.37%)
Streaming Delayed Price
Updated: 2:10 PM EDT, Aug 10, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Regeneron Pharmaceuticals
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Today 10:56 EDT
From
Schall, Brown & Schwartz LLP
Via
GlobeNewswire
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm
August 07, 2026
From
Schall, Brown & Schwartz LLP
Via
GlobeNewswire
REGN Stock Drop: If You Lost Money Investing in Regeneron Pharmaceuticals, Inc. Contact Robbins LLP for Information About Leading the Class Action Lawsuit
August 05, 2026
From
Robbins LLP
Via
Business Wire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – REGN
August 04, 2026
From
Pomerantz LLP
Via
GlobeNewswire
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Regeneron Pharmaceuticals, Inc. (REGN)
August 04, 2026
From
Bernstein Liebhard LLP
Via
GlobeNewswire
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm
August 04, 2026
From
Schall, Brown & Schwartz LLP
Via
GlobeNewswire
Regeneron Awards $150,000 to Winners of the 2026 Regeneron Prize for Creative Innovation
July 31, 2026
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Regeneron Reports Second Quarter 2026 Financial and Operating Results
July 30, 2026
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
REGENERNON PHARMACEUTICALS, INC. INVESTORS WITH LOSSES HAVE UNTIL SEPTEMBER 14, 2026 TO JOIN SECURITIES CLASS ACTION – Bernstein Liebhard LLP Announces Deadline
July 29, 2026
From
Bernstein Liebhard LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – REGN
July 28, 2026
From
Pomerantz LLP
Via
GlobeNewswire
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm
July 24, 2026
From
Schall Law
Via
GlobeNewswire
REGN Shareholder Alert: Regeneron Pharmaceuticals, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact Levi & Korsinsky
July 23, 2026
From
Levi & Korsinsky, LLP
Via
Business Wire
Did You Lose Money Investing in Regeneron Pharmaceuticals, Inc.? Robbins LLP Urges Investors with Significant Losses to Contact the Firm for Information About Their Rights Against REGN
July 23, 2026
San Diego, California--(Newsfile Corp. - July 23, 2026) - Robbins LLP reminds stockholders that a class action was filed on...
Via
Newsfile
Topics
Earnings
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces a Securities Fraud Class Action Lawsuit Has Been Filed Against Regeneron Pharmaceuticals, Inc. (REGN)
July 23, 2026
From
Bernstein Liebhard LLP
Via
GlobeNewswire
REGN INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Regeneron Investors of Securities Class Action Lawsuit Deadline on September 14, 2026
July 23, 2026
From
Faruqi & Faruqi, LLP
Via
Business Wire
REGENERNON PHARMACEUTICALS, INC. INVESTORS WITH LOSSES HAVE UNTIL SEPTEMBER 14, 2026 TO JOIN SECURITIES CLASS ACTION – Bernstein Liebhard LLP Announces Deadline
July 22, 2026
From
Bernstein Liebhard LLP
Via
GlobeNewswire
REGN Breaking News: Regeneron Inc. Sued for Securities Fraud after Revealing Failed Phase III Clinical Trial Resulting in 10% Stock Drop – Investors Notified to Contact BFA Law
July 21, 2026
From
Bleichmar Fonti & Auld LLP
Via
Business Wire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – REGN
July 21, 2026
From
Pomerantz LLP
Via
GlobeNewswire
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm
July 21, 2026
From
Schall Law
Via
GlobeNewswire
REGENERNON PHARMACEUTICALS, INC. (REGN) INVESTOR ALERT Investors With Large Losses in Regeneron Pharmaceuticals, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
July 20, 2026
From
Bernstein Liebhard LLP
Via
GlobeNewswire
Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – REGN
July 18, 2026
From
DJS Law Group
Via
Business Wire
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm
July 17, 2026
From
The Schall Law Firm
Via
Business Wire
REGENERON ALERT: Bragar Eagel & Squire, P.C. is Investigating Regeneron Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
July 17, 2026
From
Bragar Eagel & Squire
Via
GlobeNewswire
REGN DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Regeneron Investors of Securities Class Action Lawsuit Deadline on September 14, 2026
July 17, 2026
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
Investor Notice: Robbins LLP Informs Investors of the Regeneron Pharmaceuticals, Inc. Class Action Lawsuit
July 16, 2026
From
Robbins LLP
Via
Business Wire
Regeneron to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast
June 25, 2026
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Cemdisiran Regulatory Submissions Accepted for Review by FDA and EMA for the Treatment of Generalized Myasthenia Gravis (gMG)
June 22, 2026
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
REGN Investors Have Opportunity to Join Regeneron Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm
June 10, 2026
From
The Schall Law Firm
Via
Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN
June 09, 2026
From
Pomerantz LLP
Via
GlobeNewswire
Regeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO
June 04, 2026
Latest clinical data and research illustrate Regeneron’s advancement of innovative science for diverse and serious diseases with significant unmet needs
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
